“Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study…

The drug, tinlarebant, targets Stargardt disease type 1, a progressive eye disease causing vision loss in childhood or adolescence. It affects more than 50,000 patients in the United States, according to the company.

The company said the drug slowed the growth of damaging lesions in the retina by 36% compared to placebo in a study of 104 patients aged 12 to 20…

The eye condition currently has no FDA-approved treatments.”

From Reuters.